DE-THE-LYCRA-COMPANY
23.7.2024 11:01:35 CEST | Business Wire | Press release
The LYCRA Company, a global leader in developing innovative and sustainable fiber and technology solutions for the apparel and textile industry, has announced that its COOLMAX® EcoMade fiber made from 100% textile waste is a key ingredient in the Brazilian Volleyball team’s indoor and beach jerseys for the 2024 Summer Games in Paris. Body Work, a fitness brand from retailer Riachuelo, created the official uniforms unveiled in a stunning projection on the Christ the Redeemer statue overlooking Rio de Janeiro on June 27, Volleyball Day in Brazil.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240716778680/en/
Body Work, a fitness brand from Riachuelo, has revealed the official Brazilian Volleyball team shirts for the 2024 Summer Games. The fabric blends two technologies from The LYCRA Company: 92% COOLMAX® EcoMade fiber made from pre-consumer textile waste and 8% LYCRA® fiber to help keep athletes cool, dry, and moving freely. (Photo: Business Wire)
COOLMAX® EcoMade fiber transports moisture away from the body to the surface of the fabric, where it evaporates. This helps athletes stay cool, dry, and comfortable so they can focus on the game. It is one of many innovative branded fibers produced by The LYCRA Company designed to help optimize athletic performance. This technology converts pre-consumer textile waste scraps from garment manufacturers into fibers offering comparable performance to virgin polyester.
“We are thrilled that Brazil’s volleyball uniforms feature 92% COOLMAX® EcoMade fiber made from textile waste and 8% LYCRA® fiber, so we will be rooting for them in Paris,” said Nicolas Banyols, chief commercial officer - apparel, The LYCRA Company. “The benefits of activewear and sportswear with performance fibers are not limited to elite athletes anymore. Consumers of all abilities can now buy these innovative garments at retail, ensuring that everyone can experience the enhanced comfort and performance our fibers offer, in addition to options for durable and sustainable fibers for reduced environmental impact.”
LYCRA® brand fibers, now owned by The LYCRA Company, have been an integral part of the games since 1968, when the French alpine ski team dominated the medal count in Grenoble. The team's ski suits featured LYCRA® fiber, which provided a second-skin fit and greater freedom of movement. The long-standing history of performance and innovation in sports is a testament to the trust and reliability that the company’s fibers offer, instilling confidence in athletes and consumers alike.
“While the silver medal-winning 1984 Brazilian volleyball team uniform was the main inspiration for the design of this jersey, we wanted the fabric to be cutting-edge and future-focused,” said Camila de Paula Souza, Style Manager at Body Work | Riachuelo. “This fabric is designed to provide comfort and is made from textile waste—a win for athletes and a win for the planet.”
Consumers may purchase the official Brazilian Volleyball Team shirts at riachuleo.com. For more information on COOLMAX® EcoMade fiber benefits, visit coolmax.com.
About The LYCRA Company
The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries committed to offering sustainable products using renewable, pre-, and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at lycra.com.
COOLMAX® and LYCRA® are trademarks of The LYCRA Company.
About Riachuelo
With over 75 years of history, Riachuelo operates with the purpose of connecting desires to achievements. By combining innovation, dynamism, and agility to deliver collections and products for all styles, the brand is a leading reference in the sector and is recognized as one of the largest fashion companies in Brazil. Riachuelo boasts more than 30 million cardholders and over 400 own stores across the country.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240716778680/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom